Rodwige J. Desnoyers, M.D.
Assistant Professor, Hematology & Oncology
Esophagectomy; Esophageal Neoplasms; Radiotherapy, Adjuvant; Radiotherapy Dosage; Forecasting
Academic: 336-716-4464 | Department: 336-716-4464
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L,.. Lancet Oncol. 2017;18(6):770-778.
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED,.. J Hematol Oncol. 2017;10(1):100.
Li-Fraumeni versus Pseudo-Li-Fraumeni syndrome: key insights for interpreting next-generation sequencing reports in patients with suspected cancer predisposition syndromes. Sorscher S, Desnoyers R, Ouyang K, Ramkissoon S.. Oncologist. 2017;22(9):1084-1085.
Mutational landscapes of smoking-related cancers in Caucasians and African Americans: precision oncology perspectives at Wake Forest Baptist Comprehensive Cancer Center. Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC,.. Theranostics. 2017;7(11):2914-2923.
New promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer [abstract]. Alistar AT, Pasche B, D'Agostino R, Pardee T, Luther S, Desnoyer R.. Ann Oncol. 2017;28(Suppl 5):1733PD.
A comparison of chemotherapy regimens in the treatment of esophageal cancer with chemoradiation therapy with or without surgery [abstract]. Edmunds M, Mctyre E, Soike M, Ayala-Peacock DN, Hughes RT, Zhou Y, Munden RF, Desnoyers R, Levine E, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):E146.
The mitochondrial metabolism inhibitor CPI-613 in combination with mFOLFIRINOX for pancreatic adenocarcinoma [abstract]. Alistar AT, Desnoyer R, D'Agostino R.. J Clin Oncol. 2016;34(4 Suppl):264.
CPI-613 enhances FOLFIRINOX response rate in stage IV pancreatic cancer [abstract]. Alistar AT, Desnoyers R, D'Agostino RJ, Pasche B.. Ann Oncol. 2016;27(Suppl 6):675P.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
Assistant Professor, Hematology & Oncology
Colon and Rectal Cancer, Pancreatic Cancer, Rectal Cancer, Gastrointestinal Oncology
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
Have recomended the hospital to several people telling them about my care treatment and miraculous survival with a diagnosis of terminal pancreatic and liver cancer in 2014 still alive and kicking in 2018 thanks to clinical trial and a new drug only available at WFB.
Could not have found a more professional staff anywhere to deal with my condition (stage 4 pancreatic cancer with liver involved) I have been called the miracle man thanks to Wake Forest staff and being enrolled in the clinical trial with Cornerstone Pharmaceutical Company. I am lucky to be alive this long and with the current treatment plan on staying here for a few more years Thanks to everyone involved
After waiting more than 45 minutes, this visit was very short. I felt the information was too brief, no depth.
We have a good relationship with the medical problem but also talk about personal experiences on several different subjects.
*Dr. Rodwige J.Desnoyers & asst. were wonderful.
I think he is very good technically. It is just difficult to speak with him when there is no appointment. It takes days for him to respond to requests, either via mywakehealth.org or via leaving a message.